Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProBioGen Launches Unique Portfolio of Engineered High-Performance Cell Lines

Published: Monday, November 12, 2012
Last Updated: Monday, November 12, 2012
Bookmark and Share
Royalty-free biopharmaceutical CHO production cell lines, individually optimized for enhanced ADCC activity, adjusted galactosylation levels and/or increased production of the target antibodies or proteins.

This elaborate cellular toolbox allows the rapid and targeted creation of antibody and protein molecules with specific pre-defined properties.

The cell's fitness for purpose can either be proven via fee-for-service-based demonstration studies at ProBioGen or by providing the cell lines under research licenses to interested parties. The engineered cell lines are royalty-free and are suitable for clinical and commercial production. All engineered cells are based on ProBioGen's biopharmaceutical CHO platform of DG44 and K1 cell lines and can be freely combined with ProBioGen's stable expression vector system and chemically defined media platform.

Besides applying the described permanent cell modifications to newly created cells lines and molecules, all technologies can also be rapidly introduced into existing protein producer cell lines and even into any clients' own expression platforms.

CHO cells with the following modifications are available:

The GlymaxX® technology boosts antibody ADCC activity by preventing the addition of the sugar "fucose" to the N-linked antibody carbohydrate part in antibody-producing cells. The GlymaxX® technology is based on the introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis. GlymaxX® is universally applicable to different CHO hosts and to any other eukaryotic cell line; it is also simple and potent. It can be applied in a few weeks to any existing antibody producer cell line, or can be included into newly developed cell lines. ProBioGen offers this technology royalty-free to third parties.

The Galactosylation Adjustment Technology is a genetically controlled way to adjust protein galactosylation levels through the additional presence of an enzyme in the producer cells (as opposed to media supplementation to influence galactosylation levels). CHO cells predominantly produce G0 structures (no Galactose molecules).Galactosylation adjustment can increase protein drug galactosylation to almost maximal extent (G2).

The gradual activity of this stably transfected enzyme allows a carefully adjusted or maximized galactosylation of antibodies or proteins. This is desirable e.g. for matching originators galactosylation levels when developing biosimilars, for half-life extension or other reasons.

The Pathway Modulator Technology is highly versatile and readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity. It works through the additional expression of an engineered non-human enzyme in the producer cells. Upon stable transfection, the modulator enzymes' concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs. For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification increased yields between 1.3 and 2.6-fold.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProBioGen, Eucodis Sign Agreement
Company has signed an exclusive license agreement with Eucodis Bioscience to commercialize C-LiNK, a novel antibody drug conjugation technology.
Wednesday, April 20, 2016
ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals
ProBioGen to contribute producer cell line development and process engineering for Virdante’s therapeutic protein.
Wednesday, April 28, 2010
Scientific News
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
‘NoBody,’ a Microprotein On a Mission
Researchers identify over 400 microproteins encoded in the human genome, one of which clears unneeded genetic material inside cells.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Largest Resource of Protein-Protein Interactions
Researchers have developed the largest ever database of protein-protein interactions.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Building Better Nanodiscs
Researchers have improved upon the design of nanodiscs that provide an unprecedented view of viral infection.
Protein-Folding Gene Helps Heal Wounds
Researchers identified a protein that dramatically accelerates wound healing in animal models.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!